相似文献
1
Synthesis and biological evaluation of rapamycin-derived, next generation small molecules.
Medchemcomm. 2017 Nov 22;9(1):27-43. doi: 10.1039/c7md00474e. eCollection 2018 Jan 1.
2
The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.
J Biol Chem. 2007 May 4;282(18):13395-401. doi: 10.1074/jbc.M700498200. Epub 2007 Mar 9.
3
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer Res. 1999 Feb 15;59(4):886-94.
4
The FRB domain of mTOR: NMR solution structure and inhibitor design.
Biochemistry. 2006 Aug 29;45(34):10294-302. doi: 10.1021/bi060976+.
5
Why Is Rapamycin Not a Rapalog?
Gerontology. 2023;69(6):657-659. doi: 10.1159/000528985. Epub 2023 Jan 7.
6
Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP-FRB Interaction and Autophagy.
Cells. 2022 Jan 24;11(3):385. doi: 10.3390/cells11030385.
7
Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR.
Br J Pharmacol. 2009 Oct;158(4):1112-20. doi: 10.1111/j.1476-5381.2009.00369.x. Epub 2009 Sep 25.
8
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Data Brief. 2021 Feb 10;35:106858. doi: 10.1016/j.dib.2021.106858. eCollection 2021 Apr.
9
Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.
J Control Release. 2013 Nov 10;171(3):330-8. doi: 10.1016/j.jconrel.2013.05.013. Epub 2013 May 25.
10
Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library.
ACS Comb Sci. 2011 Sep 12;13(5):486-95. doi: 10.1021/co200057n. Epub 2011 Jul 28.
引用本文的文献
1
Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistance.
Oncogenesis. 2025 Jul 23;14(1):26. doi: 10.1038/s41389-025-00568-z.
2
Unraveling the therapeutic landscape of approved non-peptide macrocycles.
Acta Pharm Sin B. 2025 Jul;15(7):3436-3459. doi: 10.1016/j.apsb.2025.04.021. Epub 2025 Apr 25.
3
Combined Deep Learning and Molecular Modeling Techniques on the Virtual Screening of New mTOR Inhibitors from the Thai Mushroom Database.
ACS Omega. 2023 Oct 2;8(41):38373-38385. doi: 10.1021/acsomega.3c04827. eCollection 2023 Oct 17.
4
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease.
Signal Transduct Target Ther. 2023 Oct 2;8(1):375. doi: 10.1038/s41392-023-01608-z.
5
Isoginkgetin, a potential CDK6 inhibitor, suppresses enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma.
Autophagy. 2023 Apr;19(4):1221-1238. doi: 10.1080/15548627.2022.2119353. Epub 2022 Sep 13.
6
In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules.
Molecules. 2021 Feb 19;26(4):1103. doi: 10.3390/molecules26041103.
7
Evaluation of NMU-Induced Breast Cancer Treated with Sirolimus and Sunitinib on Breast Cancer Growth.
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):2919-2925. doi: 10.31557/APJCP.2020.21.10.2919.
8
In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives.
Nat Commun. 2020 Aug 11;11(1):4022. doi: 10.1038/s41467-020-17769-2.
9
Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel.
Int J Nanomedicine. 2019 Aug 5;14:6249-6268. doi: 10.2147/IJN.S216432. eCollection 2019.
10
Rapamycin-inspired macrocycles with new target specificity.
Nat Chem. 2019 Mar;11(3):254-263. doi: 10.1038/s41557-018-0187-4. Epub 2018 Dec 10.
本文引用的文献
1
Twenty-five years of mTOR: Uncovering the link from nutrients to growth.
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11818-11825. doi: 10.1073/pnas.1716173114. Epub 2017 Oct 25.
2
Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
Transplantation. 2017 Dec;101(12):2830-2840. doi: 10.1097/TP.0000000000001933.
3
A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
Anticancer Res. 2017 Jul;37(7):3397-3403. doi: 10.21873/anticanres.11706.
4
4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1.
Protein Cell. 2016 Dec;7(12):878-887. doi: 10.1007/s13238-016-0346-6. Epub 2016 Dec 1.
5
Tor forms a dimer through an N-terminal helical solenoid with a complex topology.
Nat Commun. 2016 Apr 13;7:11016. doi: 10.1038/ncomms11016.
6
Architecture of human mTOR complex 1.
Science. 2016 Jan 1;351(6268):48-52. doi: 10.1126/science.aaa3870. Epub 2015 Dec 17.
7
Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells.
Curr Opin Chem Biol. 2015 Oct;28:194-201. doi: 10.1016/j.cbpa.2015.09.003. Epub 2015 Sep 29.
8
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
J Med Chem. 2015 Jul 23;58(14):5599-608. doi: 10.1021/acs.jmedchem.5b00627. Epub 2015 Jul 8.
9
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.
J Med Chem. 2015 Jul 9;58(13):5323-33. doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26.
10
Light-cleavable rapamycin dimer as an optical trigger for protein dimerization.
Chem Commun (Camb). 2015 Apr 4;51(26):5702-5. doi: 10.1039/c4cc09442e.
Zotero 插件